Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5711228 | 1.00 | PPM1D (0.38) | PPM1DCNR2 | |
| SCHEMBL9985676 | 1.00 | PPM1D (0.38) | PPM1DCNR2 | |
| SCHEMBL5711230 | 1.00 | PPM1D (0.38) | PPM1DCNR2 | |
| SCHEMBL25382185 | 0.96 | PPM1D (0.35) | PPM1D | |
| SCHEMBL661089 | 0.89 | PPM1D (0.34) | PPM1D | |
| SCHEMBL5831542 | 0.89 | PPM1D (0.34) | PPM1D | |
| SCHEMBL20758481 | 0.89 | PPM1D (0.34) | PPM1D | |
| SCHEMBL360950 | 0.89 | PPM1D (0.36) | PPM1D | |
| SCHEMBL1015667 | 0.89 | PPM1D (0.34) | PPM1D | |
| SCHEMBL18535817 | 0.89 | PPM1D (0.34) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250179027-A1 | CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2025-06-05 | — | — | US | disclosed |
| EP-4474377-A1 | CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | Shenzhen TargetRx, Inc. (CN) | 2024-12-11 | — | — | EP | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-117510491-A | Compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides | 阿尔维纳斯运营股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-110741004-B | Compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides | 阿尔维纳斯运营股份有限公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2023165570-A1 | CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2023-09-07 | — | — | WO | disclosed |
| CN-116693458-A | Cycloalkyl or heterocyclyl substituted heteroaryl compounds, compositions and uses thereof | 深圳市塔吉瑞生物医药有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| EP-1599433-B1 | METHOD FOR PRODUCING THE ENANTIOMERIC FORMS OF CIS 1,3-CYCLOHEXANEDIOL DERIVATIVES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-12-06 | — | — | EP | disclosed |
| US-7094795-B2 | Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-08-22 | — | — | US | disclosed |
| EP-1599433-A1 | METHOD FOR PRODUCING THE ENANTIOMERIC FORMS OF CIS 1,3-CYCLOHEXANEDIOL DERIVATIVES | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | ELI LILLY AND COMPANY | 2005-01-27 | — | — | US | disclosed |
| US-20040209931-A1 | Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-21 | — | — | US | disclosed |
| WO-2004076390-A1 | METHOD FOR PRODUCING THE ENANTIOMERIC FORMS OF CIS 1,3-CYCLOHEXANEDIOL DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
| US-6355640-B1 | TREATMENT OF HYPERTENSION, UROGENITAL DISORDERS AND FORMED BY WITTIG REACTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-5773530-A | USEFUL AS PSYCHOSTIMULANTS, ANTIHYPERTENSIVE AGENTS AND REMEDIES FOR RENAL FAILURE, DIURETICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| EP-0737193-A1 | PYRAZOLOPYRIDINE ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995018128-A1 | PYRAZOLOPYRIDINE ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209931-A1 | Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives | CYP1A1, CYP51A1, CYP1B1 | PPM1D 3947/4885CNR2 900/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | PPM1D 800/4885CNR2 4164/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | PPM1D 800/4885CNR2 4164/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | PPM1D 1094/4885CNR2 4181/4885 |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | NCOA4, PPARG, PPARA | PPM1D 4280/4885CNR2 26/4885 |
| US-20250179027-A1 | CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | BTK, LYN, SYK | PPM1D 206/4885CNR2 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.